1443P Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
| Autor: | Gogishvili, M. 1, Melkadze, T. 2, Baramidze, A. 3, Makharadze, T. 4, He, X. 5, Gullo, G. 5, Rietschel, P. 5, Quek, R.G.W. 5 |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S821-S821 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|